Gerçek Yaşam Çalışması: Miyeloproliferatif Neoplazm Hastalarında Pegile İnterferon Alfa2a’nın Etkinliği ve Güvenliği
Abstract
Objectives: Several clinical studies have reported promising results in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
treated with pegylated interferon alpha-2a (PEG-IFN-α-2a). In this study, we evaluated the efficacy and safety of PEG-IFN-α-2a in patients with
myeloproliferative neoplasms (MPNs) followed and treated in our clinic.
Materials and Methods: In this retrospective analysis, we present the outcomes of 39 patients diagnosed with MPNs (25 with ET, 13 with PV, 1 with
primary myelofibrosis) who received PEG-IFN-α-2a between 2014 and 2021.
Results: The average age of the participants was 49 years, ranging from 23 to 71. Most patients (92%) had received at least one prior cytoreductive
therapy. The median starting dose of PEG-IFN-α-2a was 126 mcg/week (range, 22.5-180 mcg/week), administered by self-injection. The median
duration of treatment was 24 months (range, 1-77). The overall response rates in patients with PV and ET were 84.6% and 92%, respectively. The
most common adverse events observed during the treatment period were fatigue (71%), myalgia (54%), and arthralgia (53%).
Conclusion: Our results suggest that PEG-IFN-α-2a remains a feasible treatment option, particularly for younger patients who wish to avoid
prolonged cytotoxic therapy.
Keywords
Pegylated interferon alpha-2a, polycythemia vera, essential thrombocythemia
Ethical Statement
Ethics Committee Approval: The study was approved by the Ankara University Faculty of Medicine Human Research
Ethics Committee (date: 10.12.2021, approval no.: İ10-663-21).
References
- Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29:573-582.
- 2. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168-2181.
- 3. Platanias LC. Mechanisms of type-I- and type-II-interferon mediated signalling. Nature Reviews Immunol. 2005;5:375-386.
- 4. Kiladjian J-J, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776-781.
- 5. Gowina K, Jaina T, Kosiorek H, et al. Pegylated interferon alpha-2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leukemia Research. 2017;54:73-77.
- 6. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418-5424.
- 7. Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients, Haematologica. 2012;10:1570-1573.
- 8. Utke Rank C, Bjerrum OW, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57:348-354.
- 9. Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/ intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21:277-280.
- 10. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European Leukemia Net consensus conference. Blood. 2009;113:4829-4233.